Bayer is lobbying U.S. states to adjust their regulations in the battle to control costly litigation targeting its herbicide ...

Bayer is lobbying U.S. states to adjust their regulatory framework in its battle to wind down costly litigation over its ...

With almost 13 out of every million people in the US diagnosed per year, it is one of the most common autoimmune kidney diseases, and each person’s journey is unique, the pharma major stated.

“2025 is a landmark launch year for Bayer Pharmaceuticals, and we are pulling out all stops to drive the power of our pipeline,” said Stefan Oelrich, Member of the Board of ...

(Yicai) April 2 -- Bayer Pharmaceuticals is poised for a transformative year as it advances multiple blockbuster launches globally, with particular focus on China, while facing the challenge of losing ...

The National Pharmaceutical Pricing Authority (NPPA) has directed Bayer Zydus Pharma, a joint venture between Bayer and Zydus Lifesciences, to continue production and sales of various strengths and ...

BERLIN, March 28, 2025--(BUSINESS WIRE)--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment ...

M.D., Head of Business Development and Licensing at Bayer’s Pharmaceuticals Division. “The highly selective targeting of cancer cells while sparing healthy cells, based on the innovative mechanism of ...

The activist’s discussions underscore the issues facing Bayer, with the troubled pharmaceuticals-to-agriculture group in the midst of a complicated turnaround plan under its new chief executive ...

The Trump ad­min­is­tra­tion’s threat­ened tar­iffs on Eu­rope would be painful for the biotech in­dus­try, ac­cord­ing to da­ta from a sur­vey con­duct­ed by the in­dus­try’s ...

Looking ahead, this article highlights the key trends expected to shape the regulatory landscape of pharmaceutical manufacturing in 2025. Regulatory agencies—including the U.S. Food and Drug ...

FRANKFURT, March 26 (Reuters) - Bayer (BAYGn.DE), opens new tab said on Wednesday it struck a global licence agreement for an experimental oral cancer drug for targeted therapies with China's Puhe ...